There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial
NCT04684719
Recruiting
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to standard of care resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age.
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
03/22/2024
Locations: University of Cincinatti, Cincinnati, Ohio
Conditions: Hemorrhagic Shock, Traumatic Injury
Register for Updates
Study of INKmune in Patients With mCRPC (CaRe Prostate)
NCT06056791
Recruiting
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Carl & Edyth Lindner Center for Research and Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati, Ohio
Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
Register for Updates
M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study
NCT04982835
Recruiting
Prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/22/2024
Locations: Mayfield Clinic, Cincinnati, Ohio
Conditions: Cervical Disc Degenerative Disorder
Register for Updates
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
Recruiting
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy a... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/21/2024
Locations: Research Site, Cincinnati, Ohio
Conditions: Muscle Invasive Bladder Cancer
Register for Updates
Pediatric Obesity Weight Evaluation Registry (POWER) Study
NCT02121132
Recruiting
The main objective of this study is to establish a national pediatric obesity registry known as POWER (Pediatric Obesity Weight Evaluation Registry). This registry will contain clinical data from individual comprehensive pediatric weight management programs around the United States for overweight and obese youth.
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Overweight, Obesity
Register for Updates
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439
Recruiting
SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication.
NCT06335758
Recruiting
The goal of this observational study is to evaluate the safety, efficacy and patient satisfaction with the ReX Remote Digital Nurse by patients receiving solid oral medication. The study will evaluate and monitor use of ReX in respect of: treatment duration adverse events patient adherence and compliance engagement with ReX via patient-reported outcomes Patients participating in the study will receive their normal medication as standard of care via ReX. Progress will be monitored via patients... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: OHC, Cincinnati, Ohio
Conditions: Any Solid Oral Medication
Register for Updates
Vincristine Pharmacokinetics in Infants
NCT05359237
Recruiting
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence... Read More
Gender:
All
Ages:
12 years and below
Trial Updated:
03/21/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
NO During CPB in Neonates to Reduce Risk of AKI
NCT04216927
Recruiting
Acute kidney injury (AKI) following cardiac surgery for congenital heart defects (CHD) in children affects up to 60% of high risk-patients and is a major cause of both short- and long-term morbidity and mortality. Despite effort, to date, no successful therapeutic agent has gained widespread success in preventing this postoperative decline in renal function. Nitric oxide is an intricate regulator of acute inflammation and coagulation and is a potent vasodilator. The investigators hypothesize tha... Read More
Gender:
All
Ages:
Between 1 day and 31 days
Trial Updated:
03/21/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: AKI, CHD - Congenital Heart Disease, Surgery
Register for Updates
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis
NCT04891640
Recruiting
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Gender:
All
Ages:
Between 8 years and 21 years
Trial Updated:
03/21/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Juvenile Spondyloarthritis
Register for Updates
Management of the PDA Trial
NCT03456336
Recruiting
Estimate the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.
Gender:
All
Ages:
Between 48 hours and 21 days
Trial Updated:
03/20/2024
Locations: Cincinnati Children's Medical Center, Cincinnati, Ohio
Conditions: Infant, Premature, Patent Ductus Arteriosus, Infant, Newborn, Diseases, Patent Ductus Arteriosus After Premature Birth
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio +1 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates